Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Priorix

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
BACKGROUND Chikungunya is an emerging arthropod-borne disease that has spread from tropical endemic areas to more temperate… Expand
  • figure 1
  • table 1
  • figure 3
  • table 3
  • table 2
Highly Cited
2014
Highly Cited
2014
BACKGROUND In July 2006, Priorix-Tetra™, a combined measles-mumps-rubella-varicella (MMRV) vaccine, was licensed in Germany… Expand
2011
2011
Background: Antibodies against Haemophilus influenzae type b (Hib) and serogroup C Neisseria meningitidis (MenC) wane after early… Expand
2011
2011
Background:  Although MMR vaccine is widely used in Korea, there are limited studies on the currently used vaccines. We evaluated… Expand
Highly Cited
2007
Highly Cited
2007
Measles-mumps-rubella (MMR) vaccines containing the Urabe strain of mumps were withdrawn in the United Kingdom in 1992 following… Expand
  • table 2
Highly Cited
2006
Highly Cited
2006
Background: Combination vaccines against common childhood diseases are widely used, provide an improved coverage, are more… Expand
2006
2006
The aim of this study was to investigate whether, the vaccine Priorix causes less immediate injection pain than MMR-II in… Expand
2004
2004
OBJECTIVE To compare acute pain response to 2 measles-mumps-rubella vaccines. DESIGN Double-blind clinical trial. SETTING… Expand
  • table 1
  • table 2
  • table 4
  • table 3
2004
2004
The aim of this study was to compare self-reported immediate post-vaccination pain and safety of Priorix versus RORVax in 4- to 6… Expand
Highly Cited
1999
Highly Cited
1999
OBJECTIVE To compare the reactogenicity and immunogenicity of a novel live attenuated measles-mumps-rubella vaccine, SB MMR… Expand